Literature DB >> 28819084

The Significance of Lactate and Lipid Peaks for Predicting Primary Neuroepithelial Tumor Grade with Proton MR Spectroscopy.

Hisao Nakamura1, Masatomo Doi2, Takuya Suzuki1, Yasuyuki Yoshida3, Masahiro Hoshikawa2, Masashi Uchida3, Yuichiro Tanaka3, Masayuki Takagi2, Yasuo Nakajima1.   

Abstract

PURPOSE: 1H-MRS is a non-invasive technique used to assess the metabolic activity of brain tumors. The technique is useful for the preoperative prediction of tumor grade, which is important for treatment planning and accurate prognosis. We used 1H-MRS to study the lactate peak, which appears in various conditions, including hyperglycemia, ischemia, and hypoxia and lipid peak, which is associated with necrotic cells. The purpose of this study was to retrospectively examine the frequency and significance of lactate and lipid peaks in relation to brain tumor grade.
MATERIALS AND METHODS: Fifty-five patients diagnosed with neuroepithelial tumors of Grades I (3 cases), II (11 cases), III (15 cases), and IV (26 cases) were enrolled. Biopsies were excluded. Single voxel (TE = 144 ms) point resolved 1H-MRS spectroscopy sequences were retrospectively analyzed. An inverted doublet peak at 1.3 ppm was defined as lactate, a negative and positive peak was defined as combined lactate and lipid, and a clear upward peak was defined as lipid.
RESULTS: Lactate peaks were detected in all grades of brain tumors and were least common in Grade II tumors (9.1%). The frequency of combined lactate-lipid peaks was 0% (Grades I and II), 8.3% (Grade III), and 44% (Grade IV). Grade IV tumors were significantly different to the other grades. There were three cases with a lipid peak. All were glioblastoma.
CONCLUSIONS: The presence of a lac peak may be useful to largely rule out the Grade II tumors, and allow the subsequent differentiation of Grade I tumors from Grade III or IV tumors by conventional imaging. The presence of a lipid peak may be associated with Grade IV tumors.

Entities:  

Keywords:  brain tumor; glioma; lactate; lipid; magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2017        PMID: 28819084      PMCID: PMC6039781          DOI: 10.2463/mrms.mp.2017-0042

Source DB:  PubMed          Journal:  Magn Reson Med Sci        ISSN: 1347-3182            Impact factor:   2.471


  22 in total

1.  In vivo 1H-spectroscopy of human intracranial tumors at 1.5 tesla. Preliminary experience at a clinical installation.

Authors:  O Henriksen; S Wieslander; F Gjerris; K M Jensen
Journal:  Acta Radiol       Date:  1991-03       Impact factor: 1.990

2.  Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors.

Authors:  R D Tien; P H Lai; J S Smith; F Lazeyras
Journal:  AJR Am J Roentgenol       Date:  1996-07       Impact factor: 3.959

Review 3.  The clinical value of proton magnetic resonance spectroscopy in adult brain tumours.

Authors:  N A Sibtain; F A Howe; D E Saunders
Journal:  Clin Radiol       Date:  2007-02       Impact factor: 2.350

Review 4.  Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism.

Authors:  Tracy Richmond McKnight
Journal:  Semin Oncol       Date:  2004-10       Impact factor: 4.929

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.

Authors:  H J Eyre; J J Crowley; J J Townsend; J R Eltringham; R A Morantz; S F Schulman; J M Quagliana; M al-Sarraf
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

7.  Utility of multiparametric 3-T MRI for glioma characterization.

Authors:  Bhaswati Roy; Rakesh K Gupta; Andrew A Maudsley; Rishi Awasthi; Sulaiman Sheriff; Meng Gu; Nuzhat Husain; Sudipta Mohakud; Sanjay Behari; Chandra M Pandey; Ram K S Rathore; Daniel M Spielman; Jeffry R Alger
Journal:  Neuroradiology       Date:  2013-02-02       Impact factor: 2.804

8.  Multiparametric differentiation of posterior fossa tumors in children using diffusion-weighted imaging and short echo-time 1H-MR spectroscopy.

Authors:  J F Schneider; S Confort-Gouny; A Viola; Y Le Fur; P Viout; M Bennathan; F Chapon; D Figarella-Branger; P Cozzone; N Girard
Journal:  J Magn Reson Imaging       Date:  2007-12       Impact factor: 4.813

9.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy.

Authors:  H Shimizu; T Kumabe; T Tominaga; T Kayama; K Hara; Y Ono; K Sato; N Arai; S Fujiwara; T Yoshimoto
Journal:  AJNR Am J Neuroradiol       Date:  1996-04       Impact factor: 3.825

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  2 in total

Review 1.  Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

2.  Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites.

Authors:  Raúl Vicente Casaña-Eslava; Sandra Ortega-Martorell; Paulo J Lisboa; Ana Paula Candiota; Margarida Julià-Sapé; José David Martín-Guerrero; Ian H Jarman
Journal:  PLoS One       Date:  2020-07-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.